Company is expecting an FDA-483 inspection report at the end of March following an ongoing pre-approval inspection of Building 358 in Indianapolis. Because the inspection closely follows a warning letter related to a pre-approval inspection for Zyprexa IM, global process changes have yet to be implemented, Lilly said (1"The Pink Sheet" March 12, p. 26). The firm continues to expect a launch for the osteoporosis drug Forteo (teriparatide) during the fourth quarter. A recent inspection of a Lilly plant in Puerto Rico resulted in few observations and no 483, the company added
You may also be interested in...
Lilly hopes to be ready for a re-inspection of its intramuscular Zyprexa production facility in mid-May, ahead of the late June user fee deadline for a decision on the new formulation of the antipsychotic.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials